



Antipsychotics: 70 Years

Guest Editors:

Dr. Giovanni Lentini

Department of Pharmacy-
Pharmaceutical Sciences,
University of Bari Aldo Moro, Bari,
Italy

Prof. Dr. Serge Mignani

1. Laboratoire de Chimie et de
Biochimie Pharmacologiques et
Toxicologique, Université Paris
Descartes, PRES Sorbonne Paris
Cité, CNRS UMR 860, 45, rue des
Saints Peres, 75006 Paris, France
2. CQM-Centro de Química da
Madeira, MMRG, Universidade da
Madeira, Campus da Penteada,
9020-105 Funchal, Portugal

Message from the Guest Editors

The introduction of antipsychotic agents in the 1950s was shortly followed by a tremendous reduction of institutionalized patients. While general political decisions also contributed to deinstitutionalization, it is doubtful whether it would have been possible to the same extent without the availability of effective medication. The discovery of chlorpromazine is generally considered the Big Bang of modern psychopharmacology.

This commemorative Special Issue was conceived as an opportunity to take stock of the situation, obtain an up-to-date landscape on the most recent developments, and promote advances in the challenging area of the most disabling psychiatric disorders.

Deadline for manuscript
submissions:

closed (31 May 2023)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)